Descrizione Del Prodotto

6-APB Capsules 100mg

6-APB Capsules 100mg (6-(2-aminopropyl)benzofuran), commonly known as Benzofury, is a synthetic entactogen and stimulant of the benzofuran class. It is not approved for any medical use and is classified as a novel psychoactive substance (NPS). A 100mg capsule is generally considered a strong to very strong dose (common reported oral doses range from 50–130mg, with many users recommending starting lower, around 50–80mg).

Farmacologia

6-APB acts as a serotonin–norepinephrine–dopamine releasing agent (SNDRA) with potent activity at monoamine transporters. It is a full or high-efficacy agonist at the 5-HT2B receptor (stronger than many other compounds) and also shows activity at 5-HT2A and 5-HT2C receptors. This produces MDMA-like entactogenic effects (euphoria, empathy, sociability) along with stimulant and mild psychedelic properties.

• Inizio (orale): 30–90 minuti
• Picco: 2–4 ore
• Durata: 6–12 hours (often longer than MDMA, with noticeable after-effects)

Profilo di sicurezza acuta

• Cardiovascolare: Increased heart rate, blood pressure, vasoconstriction, palpitations, and potential chest pain. Strong 5-HT2B agonism raises concerns for cardiotoxicity, especially with repeated use.
• Neurological/Psychiatric: Euphoria, empathy, sensory enhancement, but also anxiety, agitation, insomnia, paranoia, and in some cases acute psychosis (particularly when combined with other substances).
• Other Common Effects: Hyperthermia, sweating, jaw clenching (bruxism), nausea, dry mouth, muscle tension, and insomnia.

100mg significantly increases the risk of intense effects, overheating, cardiovascular strain, and difficult comedowns.

Toxicity & Reported Harms

• Cardiotoxicity: Potent 5-HT2B receptor agonism is associated with risk of heart valve damage (valvulopathy) and other cardiac issues with long-term or repeated use.
• Neurotossicità: Suspected serotonergic neurotoxicity similar to MDMA, though human data is limited.
• Fatalities: 6-APB has been linked to multiple deaths (often in combination with other drugs), hospitalizations, and severe intoxications. It has been implicated in drug-related deaths in the UK and elsewhere.
• Hepatotoxicity: In vitro studies show potential liver cell toxicity.

Interazioni farmacologiche e controindicazioni

• Alto rischio: Other serotonergic substances (MDMA, SSRIs, MAOIs) — greatly increased risk of serotonin syndrome.
• Attenzione: Stimulants, alcohol, cannabis, or any drugs affecting heart rate, temperature, or blood pressure.
• Strongly contraindicated for individuals with cardiovascular disease, hypertension, liver problems, mental health disorders (especially anxiety or psychosis), or during pregnancy/breastfeeding.

Product-Related Risks

Unregulated capsules frequently have inconsistent dosing, purity issues, or may contain mixtures of 5-APB/6-APB isomers or other substances. Effects can vary significantly between batches.

Status giuridico (al 2026)

6-APB is controlled in many countries (e.g., UK Class B, Australia, Germany, Canada, China, and others). It is banned or heavily restricted in most jurisdictions and may fall under analogue laws elsewhere.

Nota Importante: This is a neutral, educational overview based on available scientific literature, case reports, and toxicology data. There are very limited clinical safety studies on 6-APB in humans, and significant uncertainties remain regarding both short- and long-term risks. This information does non encourage use. 6-APB carries real potential for acute toxicity, cardiovascular harm, neurotoxicity, and dependence. Consult a qualified healthcare professional for any health concerns and comply with all local laws.

Ulteriori Informazioni